PA
ALDX icon

Pineridge Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Pineridge Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.13K Buy
+600
New +$3.13K ﹤0.01% 330

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Pineridge Advisors's ALDX Position: Q3 2025 in Review

Pineridge Advisors opened a new position in Aldeyra Therapeutics (ALDX) in Q3 2025: 600 shares worth $3.13K. The stake represents ﹤0.01% of the portfolio and ranks #330 among its holdings.

130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

  • Pineridge Advisors held 600 shares of Aldeyra Therapeutics worth $3.13K as of Q3 2025.
  • Aldeyra Therapeutics was a new Pineridge Advisors position in Q3 2025.
  • Aldeyra Therapeutics made up ﹤0.01% of Pineridge Advisors's portfolio in Q3 2025, its #330 holding.
  • 130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Pineridge Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.